Abstract:Background: THBS2, a member of the extracellular matrix glycoprotein family, can effectively inhibit tumour growth and angiogenesis. This study aimed to investigate the biological role of THBS2 in various types of cancers and the mechanisms underlying the malignant progression of colorectal cancer (CRC). Methods: THBS2 expression in pan-cancer tissues and cell lines was assessed using the HPA, TISCH and CCLE databases. The CIBERSORT, ESTIMATE, TIMER, xCell and ssGSEA (implemented using the IOBR R package) algorithms were used to calculate the proportion of tumour-infiltrating immune cells based on the expression profile of THBS2 in TCGA-COAD cohort. The clusterprofiler R package was used to implement GO and KEGG pathway enrichm SNVs were compared between the high- and low-THBS2-expression groups using the maftools R package. Additionally, immunotherapy responses were compared between the high- and low-THBS2-expression groups based on immunophenoscores (IPSs). CT26 cells were engineered to overexpress THBS2 (CT26-THBS2) to investigate its regulatory effects on HIF1 and cellular metabolism. The conditioned medium from CT26-THBS2 cells was collected to examine its effect on the M2 polarisation of RAW264.7 macrophages. Subsequently, in vitro experiments were performed to validate the inhibitory effects of M2-polarised macrophages on T-cell proliferation and cytotoxicity. A CT26-THBS2 tumour-bearing mouse model was constructed to validate the impact of high THBS2 expression in tumour cells on the tumour microenvironment in vivo. Results: THBS2 expression was upregulated in a majority of tumours, including COAD, and was positively associated with ESTIMATEScore, ImmuneScore and StromalScore. Furthermore, THBS2 expression was positively associated with angiogenesis and epithelial-mesenchymal transition and negatively associated with DNA repair, cell cycle and DNA replication in most tumours. THBS2 expression was considerably associated with progression-free interval (PFI) and positively associated with MSI in COAD. THBS2 methylation levels were remarkably lower in COAD tissues than in healthy tissues. The high expression of THBS2 in CT26 cells remarkably promoted the nuclear translocation of HIF1 and consequently enhanced lactate metabolism in cells. In vitro and in vivo experiments revealed that lactate released by tumour cells promoted M2 polarisation of macrophages, leading to inhibition of T-cell proliferation and cytotoxicity. Conclusions: THBS2 expression is associated with PFI, immune cell infiltration, immune regulation, cell death, cell migration, epithelial-mesenchymal transition, angiogenesis and genomic variations in COAD. THBS2 may serve as a biomarker for immunotherapy in COAD. Upregulated THBS2 expression in CRC cells inhibits anti-tumour immunity through the HIF1A/lactic acid/GPR132 pathway.

Can Thymosin Beta 10 Function Both As a Non-Invasive Biomarker and Chemotherapeutic Target in Human Colorectal Cancer?

Thymosin Beta 10 is a Key Regulator of Tumorigenesis and Metastasis and a Novel Serum Marker in Breast Cancer

Pan-cancer Analysis Identifies the Correlations of Thymosin Beta 10 with Predicting Prognosis and Immunotherapy Response

TMSB10 Promotes Migration and Invasion of Cancer Cells and is a Novel Prognostic Marker for Renal Cell Carcinoma.

The Clinical Relevance and Functional Implications of Thymosin Beta-10 in Glioma

Advances in Thymosin β10

Pancancer landscape analysis of the thymosin family identified TMSB10 as a potential prognostic biomarker and immunotherapy target in glioma

Thymosin Α-1 in Cancer Therapy: Immunoregulation and Potential Applications

Thymosin α1 combined with XELOX improves immune function and reduces serum tumor markers in colorectal cancer patients after radical surgery

TBC1D10B Promotes Tumor Progression in Colon Cancer Via PAK4‑mediated Promotion of the PI3K/AKT/mTOR Pathway.

THBS1 facilitates colorectal liver metastasis through enhancing epithelial–mesenchymal transition

TBL1XR1 Predicts Isolated Tumor Cells and Micrometastasis in Patients with TNM Stage I/II Colorectal Cancer

Identification Of Cancer-Associated Proteins By Proteomics And Downregulation Of Beta-Tropomyosin Expression In Colorectal Adenoma And Cancer

Kallikrein-related peptidase 10 predicts prognosis and mediates tumor immunomodulation in colorectal cancer

CTPS1 inhibition suppresses proliferation and migration in colorectal cancer cells.

High Expression of Thymosin Beta 10 Predicts Poor Prognosis for Hepatocellular Carcinoma after Hepatectomy

Thymosin β4: a potential molecular target for tumor therapy.

Expression of Thymidine Phosphorylase in Human Colorectal Carcinoma and Its Clinical Significance

Systematic analysis of integrated bioinformatics to identify upregulated THBS2 expression in colorectal cancer cells inhibiting tumour immunity through the HIF1A/Lactic Acid/GPR132 pathway

TMSB4X: A novel prognostic marker for non-small cell lung cancer

TYMS-TM4SF4 Axis Promotes the Progression of Colorectal Cancer by EMT and Upregulating Stem Cell Marker.